The number of women who've been handed a new asthma diagnosis in their forties — or told their existing one is 'just getting worse with age' — without anyone mentioning hormones is genuinely frustrating. Breathing feels like the most basic thing the body does, so when it starts feeling laboured or unpredictable, it's frightening in a way that hot flushes simply aren't. Connecting it to perimenopause doesn't make it less real; it makes it far more treatable.
Learn more about Rose →Estrogen receptors are found throughout the bronchial epithelium — the lining of the airways — where estrogen normally helps suppress the inflammatory signalling that drives airway narrowing and mucus overproduction. As estrogen levels become erratic and then decline during perimenopause, that anti-inflammatory brake weakens, leaving the airways more reactive to triggers they previously tolerated. This is why women with no prior respiratory history can develop what looks and feels like adult-onset asthma right in the middle of the menopause transition.
Mast cells — the immune cells that release histamine and trigger allergic-type airway responses — are directly regulated by estrogen, which normally keeps their density and activation in check. When estrogen drops, mast cell populations in lung tissue can increase and become hypersensitive, producing a histamine-driven bronchospasm that mimics classic asthma but responds poorly to standard bronchodilators alone. This same mast cell dysregulation also explains the rise in other histamine-related symptoms during perimenopause, including skin flushing, food intolerances, and nasal congestion.
Progesterone acts as a mild bronchodilator and also stimulates the respiratory drive — the brain's signal to breathe more deeply and regularly. During perimenopause, progesterone levels often fall earlier and more steeply than estrogen, quietly removing this protective effect before most women realise it's gone. The result can be a subtle but persistent sense of breathlessness or an inability to take a fully satisfying breath, sometimes described as air hunger, which is frequently mistaken for anxiety.
Women with diagnosed asthma consistently report that symptom control deteriorates during perimenopause, requiring higher medication doses or more frequent rescue inhaler use even when their environment and triggers haven't changed. Research tracking women across the menopause transition has found measurable declines in peak expiratory flow — a standard marker of airway obstruction — correlating with the drop in estrogen, independent of age alone. For these women, the culprit is often hormonal, but because the asthma diagnosis already exists, the hormonal shift goes uninvestigated.
Obstructive sleep apnoea and upper airway resistance syndrome both rise sharply in women after the menopause transition begins, with some studies showing the risk approaching — and eventually matching — that of men of the same age. Progesterone normally maintains upper airway muscle tone during sleep, so its loss allows those muscles to relax into partial obstruction far more readily. Many women are investigated for fatigue, low mood, and cognitive difficulties without anyone ordering a sleep study, when disordered breathing at night is the actual driver.
Cortisol and adrenaline — the stress hormones that spike during the HPA axis dysregulation common in perimenopause — both influence bronchial smooth muscle tone and immune activity in the lungs. Chronically elevated cortisol can paradoxically increase airway inflammation over time, even though short-term cortisol has some anti-inflammatory action, because the receptors involved in immune modulation become desensitised. Women who notice their breathing worsens during stressful periods may be experiencing this cortisol-airway feedback loop rather than a purely psychological response.
The abdominal weight gain that many women experience during perimenopause — driven by shifting fat distribution patterns as estrogen declines — physically changes the mechanics of breathing by increasing pressure on the diaphragm, particularly when lying down or seated for long periods. This mechanical load reduces functional residual capacity, meaning the lungs hold less reserve air, which makes even mild airway inflammation feel more symptomatic than it would in a different body composition. It also worsens sleep apnoea risk by narrowing the pharyngeal airway through surrounding soft tissue.
Estrogen receptors line the nasal mucosa just as they line the bronchial walls, so the same loss of estrogenic anti-inflammatory signalling that affects the lungs also affects the nose and sinuses. Perimenopausal women frequently develop chronic nasal congestion, postnasal drip, or a newly fragrant sensitivity to perfumes and cleaning products — all of which funnel irritants downward into already-reactive airways. This upper-airway component is often treated as a separate ENT problem rather than recognised as part of the same hormonal picture.
Evidence on hormone replacement therapy and asthma is genuinely mixed: some studies show estrogen therapy reduces airway hyperresponsiveness and improves lung function, while others — particularly those using oral estrogen alone — show increased asthma risk, possibly because oral estrogen raises inflammatory markers differently to transdermal delivery. Transdermal estrogen combined with progesterone appears to carry a more favourable respiratory profile, though women with significant reactive airway disease should discuss this specifically with a clinician rather than assuming HRT will automatically help or harm. The key takeaway is that hormones matter enough to the airways that any conversation about HRT should include a respiratory history.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.